1-6 of 6
Mark D. Minden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary-Elizabeth M. Percival, Anjali S. Advani, James M. Foran, Steven M. Horwitz, Matthew G. Mei, Jasmine Zain, Kerry J. Savage, Christiane Querfeld, Oleg E. Akilov, Lisa D.S. Johnson, Tina Catalano, Penka S. Petrova, Robert A. Uger, Eric L. Sievers, Anca Milea, Kathleen Roberge, Yaping Shou, Owen A. O'Connor
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (8): 2190–2199.
https://doi.org/10.1158/1078-0432.CCR-20-3706
Published: 15 April 2021
View article titled, Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression

Alison R. Walker, John C. Byrd, James S. Blachly, Bhavana Bhatnagar, Alice S. Mims, Shelley Orwick, Tara L. Lin, Howland E. Crosswell, Danjie Zhang, Mark D. Minden, Veerendra Munugalavadla, Lauren Long, Jinfeng Liu, Yang Pan, Thomas Oellerich, Hubert Serve, Arati V. Rao, William G. Blum
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5852–5859.
https://doi.org/10.1158/1078-0432.CCR-20-1064
Published: 13 November 2020
View article titled, Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <em>HOXA9</em> and <em>MEIS1</em> Expression
Open the PDF for Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <em>HOXA9</em> and <em>MEIS1</em> Expression in another window
Includes: Supplementary data
Journal Articles

Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms

JongBok Lee, Mark D. Minden, Weihsu C. Chen, Elena Streck, Branson Chen, Hyeonjeong Kang, Andrea Arruda, Dalam Ly, Sandy D. Der, Sohyeong Kang, Paulina Achita, Cheryl D'Souza, Yueyang Li, Richard W. Childs, John E. Dick, Li Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2): 370–382.
https://doi.org/10.1158/1078-0432.CCR-17-2228
Published: 15 January 2018
View article titled, Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms
Open the PDF for Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms in another window
Includes: Supplementary data
Journal Articles

Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy

Steven M. Kornblau, Mark D. Minden, David B. Rosen, Santosh Putta, Aileen Cohen, Todd Covey, David C. Spellmeyer, Wendy J. Fantl, Urte Gayko, Alessandra Cesano
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14): 3721–3733.
https://doi.org/10.1158/1078-0432.CCR-10-0093
Published: 14 July 2010
View article titled, Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy
Open the PDF for Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

Aaron D. Schimmer, Susan O'Brien, Hagop Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis Giles, Andre Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel-Reid, Mark Berger, Jean Viallet, Gautam Borthakur
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8295–8301.
https://doi.org/10.1158/1078-0432.CCR-08-0999
Published: 15 December 2008
View article titled, A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
Open the PDF for A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies in another window
Journal Articles

Cerivastatin Triggers Tumor-specific Apoptosis with Higher Efficacy than Lovastatin

W. Wei-Lynn Wong, Melissa M. Tan, Zhenlei Xia, Jim Dimitroulakos, Mark D. Minden, Linda Z. Penn
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2067–2075.
Published: 01 July 2001
View article titled, Cerivastatin Triggers Tumor-specific Apoptosis with Higher Efficacy than Lovastatin
Open the PDF for Cerivastatin Triggers Tumor-specific Apoptosis with Higher Efficacy than Lovastatin in another window